The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 16.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
Amprius Technologies, Inc.
AMPX · the NYSE · USD · Market cap $1.3B · 97 employees
Amprius Technologies, Inc.
FAIL · Does not pass the screenAt the last full screen
2026-09-15
Screened 2026-09-15 · the tape above runs as of 19:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
Amprius Technologies, Inc. holds its Markdown at $9.16. Consolidating, no directional conviction, held for 22 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 22 days |
| Price at the screen | $9.16 |
| Valuation | N/A trailing · 91.60 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.34 |
Five Screens, Shown in Full
Does not pass. Accounts receivable
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 25.41% | Below 33% | Interest-bearing debt is just 25.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 72.79% | Below 49% | Money owed to the company is 72.8% of assets, above the 49% limit. | Fail |
| Revenue purity | 3.65% | Below 5% | Only 3.6% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 31.0% margin of safety to the base estimate.
Third-party analyst targets: 9 covering, consensus None. The average target sits +140% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsHigh flying battery hopes meet eye watering valuation
Picture a startup selling batteries that could one day power electric planes. Revenue is exploding at 153 percent, yet the firm still loses 44 percent on every pound of sales and posts negative 44 percent return on equity. At 169 times forward earnings the market is paying for perfection that has not arrived, and the absence of any identifiable moat leaves little protection if execution slips.
We pass because the modest 14 percent margin of safety to our fair value does not compensate for the stretched multiple or the unknown durability of the silicon anode technology. Strong buy ratings from nine analysts and a 22 dollar median target reflect enthusiasm, not evidence that losses will turn to durable profits soon enough to justify the price.
Risk sits mainly in execution and dilution for a business that has yet to prove it can scale without burning cash. The ethical screen is clean, but that alone does not create an investment case. Analysis, not advice.
| Forward P/E | 91.6xcheap for a company growing this fast |
| EPS, trailing | -0.29 |
| EPS, forward | 0.10 |
| Revenue growth | +125.9%growing very fast |
| Profit margin | -33.4%currently unprofitable |
| Return on equity | -36.1%not currently earning a positive return on equity |
| FCF yield | -2.68% |
| Debt to equity | 0.05minimal debt: a conservative balance sheet |
| Current ratio | 7.17comfortably covers its short-term bills |
| Beta | 2.34much more volatile than the market |
| Short interest, float | 0.16% |
| 52-week range | 7.71 - 24.23 |
| Market cap | $1.3B |
| Employees | 97 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAMPX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 37.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 63% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 430%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (8 analysts) rates it strong buy, with a mean price target of $22.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $17.68 | -6.1% | · | $939 | -6.1% |
| 2 months | $17.22 | -3.6% | · | $964 | -3.6% |
| 3 months | $18.29 | -9.2% | · | $908 | -9.2% |
| 6 months | $11.44 | +45.1% | · | $1,451 | +45.1% |
| 1 year | $3.13 | +430.4% | · | $5,304 | +430.4% |
| 2 years | $1.32 | +1,157.6% | · | $12,576 | +1,157.6% |
| 3 years | $9.50 | +74.7% | · | $1,747 | +74.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AMPX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.